|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM103025561 |
| 003 |
DE-627 |
| 005 |
20250201095915.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0344.xml
|
| 035 |
|
|
|a (DE-627)NLM103025561
|
| 035 |
|
|
|a (NLM)10370379
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Triolo, G
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease
|b moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.06.1999
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We studied the in vitro E-selection expression of endothelial cells treated with sera from patients with Behçet's disease (BD) and factors (anti-endothelial cell antibodies, anti-neutrophil cytoplasmic antibodies, cytokines, and myeloperoxidase (MPO) that may contribute to adhesion molecule expression. A total of 21 patients with BD and 27 healthy controls were studied. In vitro E-selectin endothelial cell expression was investigated by ELISA after HUVEC incubation with sera or purified IgG from patients with BD and controls. Increased E-selectin expression was observed when endothelial cells were incubated with sera from patients with active disease or from patients with circulating anti-endothelial cell antibodies and high levels of plasma myeloperoxidase. Abnormalities of endothelial cell function have been suggested to play a role in the occurrence of vascular damage in BD. Our findings suggest that anti-endothelial cell antibodies and neutrophil hyperactivity, as inferred from the high plasma MPO levels in patients with active disease, may explain endothelial cell activation and neutrophil accumulation in vascular lesions
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Antineutrophil Cytoplasmic
|2 NLM
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a E-Selectin
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a anti-endothelial cell antibody
|2 NLM
|
| 650 |
|
7 |
|a Peroxidase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.11.1.7
|2 NLM
|
| 700 |
1 |
|
|a Accardo-Palumbo, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Triolo, G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carbone, M C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ferrante, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Giardina, E
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 91(1999), 3 vom: 01. Juni, Seite 330-7
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:91
|g year:1999
|g number:3
|g day:01
|g month:06
|g pages:330-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 91
|j 1999
|e 3
|b 01
|c 06
|h 330-7
|